Altus® is a pharmaceutical company focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal (GI) and metabolic diseases. These protein therapeutics are developed using Altus' proprietary and patented protein crystallization and cross-linking technology.
Our technology enables the delivery of high value protein therapeutics through both the oral and parenteral routes of delivery. Through the technology we develop robust, reproducible, and large scale processes for the production of protein crystals that can be developed as commercializable biopharmaceutical therapeutics. These products are a direct extension of our commitment to improving the quality of life of patients suffering from chronic GI and metabolic diseases.
Oral Delivery Applications
Through the use of our proprietary protein crystallization and cross-linking technology, Altus creates highly stable protein therapeutics that allow delivery of proteins to the GI tract without degrading in the harsh pH and proteolytic environment of the gut. Our product development strategy is to apply this technology to existing, well-understood proteins that would ordinarily be rendered ineffective by the harsh gastrointestinal environment. Therefore, these protein therapeutics can be taken orally, and due to their mechanism of action and therapeutic targets, do not have to be transported across the intestinal lining and into the bloodstream to demonstrate a therapeutic effect. The result is a more effective orally delivered protein with a number of benefits:
- A more convenient, patient-friendly drug
- Increased compliance leading to more effective disease management
- Improved effectiveness of treatment
- Improved stability and reproducibility
- Reduced risk of side effects.
Parenteral Delivery Applications
Our proprietary protein crystallization technology has been shown to be broadly applicable to all classes of large molecules including hormones, antibodies, cytokines, peptides, and enzymes. Through our technology, we develop products with significant improvements in the release profile and convenience of parenteral protein-based biopharmaceuticals. Protein crystal injectable products provide many benefits:
- Improved convenience with better compliance
- Controlled product delivery and release options
- Improved efficacy
- Improved safety
- Lifecycle management opportunities.
